Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) – Drugs In Development, 2024 report and make more profitable business decisions.
Idiopathic thrombocytopenic purpura is a bleeding disorder in which the immune system destroys platelets, which play important role in normal blood clotting. Symptoms include blood in urine or stools, fatigue, spontaneous bleeding from nose, and superficial bleeding into skin that appears as a rash of pinpoint sized reddish purple spots, usually on the lower legs.
The Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) drugs in development market research report provide comprehensive information on the therapeutics under development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 49 molecules, with 47 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
3SBio IncAhead Therapeutics SL
Alpine Immune Sciences Inc
Argenx SE
BeiGene Ltd
Beijing Tide Pharmaceutical Co Ltd
Biogen Inc
Biopharma Plasma
Biotest AG
BioXpress Therapeutics SA
Capital Medical University
Chia Tai Tianqing Pharmaceutical Group Co Ltd
CSPC NBP Pharmaceutical Co Ltd
Eris Lifesciences Ltd
GC Biopharma Corp
Genosco Inc
Geropharm
GSK plc
Hutchison MediPharma Ltd
Iltoo Pharma
Inmagene Biopharmaceuticals Ltd
InnoCare Pharma Ltd
Jiangsu Hengrui Medicine Co Ltd
JW Pharmaceutical Corp
KeyMed Biosciences Inc
KLUS Pharma Inc
Mabwell Therapeutics Inc
Microgen
Nanjing IASO Biotherapeutics Co Ltd
Nanjing Ruijie Pharmaceutical Technology Co Ltd
Novartis AG
NovelMed Therapeutics Inc
Peg-Bio BioPharma Co Ltd
Pfizer Inc
Pharmasyntez
PhytoHealth Corp
PlateletBio
Principia Biopharma Inc
Qilu Pharmaceutical Co Ltd
Rigel Pharmaceuticals Inc
Shandong Quangang Pharmaceutical Co Ltd
Shanghai Fosun Pharmaceutical (Group) Co Ltd
Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd
Simcere Pharmaceutical Group Ltd
Staidson BioPharma Inc
Swedish Orphan Biovitrum AB
Taiho Pharmaceutical Co Ltd
Takeda Pharmaceutical Co Ltd
Zhejiang Hisun Pharmaceutical Co Ltd
Zhejiang University School of Medicine Hospital 1
Table of Contents
Table
Figures
Frequently asked questions